News & Updates

A combination regimen comprising two herbal extracts – curcumin and Qing Dai (QD) – have shown potential in the treatment of active* ulcerative colitis (UC), according to two trials from Israel presented at Crohn’s & Colitis Congress (CCC) 2023.

Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.